Inbreeding and sex: Canalization, plasticity and sexual selection

A. Joshi

DOI: https://doi.org/10.1007/BF02715885

2005-04-01

Abstract:

What problem does this paper attempt to address?

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

Nilambra Dogra,Parminder Singh,Ashok Kumar,Dogra, Nilambra

DOI: https://doi.org/10.1007/s12035-024-04139-y

IF: 5.682

2024-04-15

Molecular Neurobiology

Abstract:Glioblastoma (GBM) is the highest grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and therapy, there has been no significant improvement in GBM outcomes, with a median overall survival continuing at a dismal 15–18 months. In recent times, glioblastoma stem cells (GSCs) have been identified as crucial drivers of treatment resistance and tumor recurrence, and GBM therapies targeting GSCs are expected to improve patient outcomes. We used a multistep in silico screening strategy to identify repurposed candidate drugs against selected therapeutic molecular targets in GBM with potential to concomitantly target GSCs. Common differentially expressed genes (DEGs) were identified through analysis of multiple GBM and GSC datasets from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). For identification of target genes, we selected the genes with most significant effect on overall patient survival. The relative mRNA and protein expression of the selected genes in TCGA control versus GBM samples was also validated and their cancer dependency scores were assessed. Drugs targeting these genes and their corresponding proteins were identified from LINCS database using Connectivity Map (CMap) portal and by in silico molecular docking against each individual target using FDA-approved drug library from the DrugBank database, respectively. The molecules thus obtained were further evaluated for their ability to cross blood brain barrier (BBB) and their likelihood of resulting in drug resistance by acting as p-glycoprotein (p-Gp) substrates. The growth inhibitory effect of these final shortlisted compounds was examined on a panel of GBM cell lines and compared with temozolomide through the drug sensitivity EC50 values and AUC from the PRISM Repurposing Secondary Screen, and the IC50 values were obtained from GDSC portal. We identified RPA3, PSMA2, PSMC2, BLVRA, and HUS1 as molecular targets in GBM including GSCs with significant impact on patient survival. Our results show GSK-2126458/omipalisib, linifanib, drospirenone, eltrombopag, nilotinib, and PD198306 as candidate drugs which can be further evaluated for their anti-tumor potential against GBM. Through this work, we identified repurposed candidate therapeutics against GBM utilizing a GSC inclusive targeting approach, which demonstrated high in vitro efficacy and can prospectively evade drug resistance. These drugs have the potential to be developed as individual or combination therapy to improve GBM outcomes.

neurosciences
Clinical evaluation of Amerlite's one-step immunoassay for determining free thyroxin.

J. Seghers,P. de Nayer,C. Beckers

DOI: https://doi.org/10.1093/CLINCHEM/34.10.2160

IF: 12.114

1988-10-01

Clinical Chemistry

Abstract:urinary 17-ketogenic steroids (17-KGS) when determined one day after radiological examination in which meglumine diatrizoate was used as contrast medium. Therefore, we decided to investigate the influence of two types of contrast materials (one ionic, meglumine diatrizoate; and one nonionic, iohexol) on the assay of urinary 17-KGS. We found a significant interference between them. Interference of meglumine diatrizoate in assays of urinary amino acids was reported previously (1). We studied six patients (five men, one woman) who underwent computed tomography (CT) scanning in which
High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Sohyon Lee,Tobias Weiss,Marcel Bühler,Julien Mena,Zuzanna Lottenbach,Rebekka Wegmann,Miaomiao Sun,Michel Bihl,Bartłomiej Augustynek,Sven P. Baumann,Sandra Goetze,Audrey van Drogen,Patrick G. A. Pedrioli,David Penton,Yasmin Festl,Alicia Buck,Daniel Kirschenbaum,Anna M. Zeitlberger,Marian C. Neidert,Flavio Vasella,Elisabeth J. Rushing,Bernd Wollscheid,Matthias A. Hediger,Michael Weller,Berend Snijder

DOI: https://doi.org/10.1038/s41591-024-03224-y

IF: 82.9

2024-09-21

Nature Medicine

Abstract:Glioblastoma, the most aggressive primary brain cancer, has a dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we systematically screened repurposable neuroactive drugs in glioblastoma patient surgery material using a clinically concordant and single-cell resolved platform. Profiling more than 2,500 ex vivo drug responses across 27 patients and 132 drugs identified class-diverse neuroactive drugs with potent anti-glioblastoma efficacy that were validated across model systems. Interpretable molecular machine learning of drug–target networks revealed neuroactive convergence on AP-1/BTG-driven glioblastoma suppression, enabling expanded in silico screening of more than 1 million compounds with high patient validation accuracy. Deep multimodal profiling confirmed Ca 2+ -driven AP-1/BTG-pathway induction as a neuro-oncological glioblastoma vulnerability, epitomized by the anti-depressant vortioxetine synergizing with current standard-of-care chemotherapies in vivo. These findings establish an actionable framework for glioblastoma treatment rooted in its neural etiology.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Do basic region-leucine zipper proteins bend their DNA targets ... does it matter?

P. Hagerman

DOI: https://doi.org/10.1073/PNAS.93.19.9993

1996-09-17

Abstract:Protein-induced bending of DNA has been described for numerous members of the large family of "basic regionleucine zipper" (bZIP) transcriptional modulators (1-4). However, for this class of proteins, there exists some uncertainty as to how much (or even whether) the bound target DNA is bent. This issue has been most sharply focused for the bZIP protein heterodimer, Fos-Jun, with two recent articles in the Proceedings (5, 6) presenting seemingly disparate views as to whether its recognition element (AP-1) is (6)-or is not (5)-bent. It has been known for some time that certain transcriptional regulators are capable of bending their DNA targets. For example, both solution (7) and crystallographic (8) studies of the Escherichia coli catabolite activator protein (CAP)-DNA complex suggest that CAP induces a -90° bend in its recognition sequence. A distortion of similar magnitude, albeit of very different local geometry, has been observed for a TATA box-binding polypeptide (9, 10). Distortions of this magnitude are highly improbable as thermal fluctuations; thus, one function of modulators such as CAP and TATA box-binding polypeptide may be to bring together otherwise distant DNA segments via protein-induced bends. In fact, tests of this general hypothesis have in some instances demonstrated that the specific function of protein-induced bends can be subserved either by heterologous protein-induced bends or by intrinsic (sequence-directed) elements ofDNA curvature (11). In 1991, Kerppola and Curran (12) reported that Fos-Jun heterodimers substantially distort the AP-1 site. Comparing the relative gel mobilities ofDNA molecules in which the AP-1 site was placed at various positions (permuted) within the molecules (circular permutation assay; refs. 13-15), those authors reported "flexure" angles of 940 for full-length FosJun, and 550 for a truncated form of the heterodimer (12). However, Kerppola and Curran (16) also performed a different form of gel experiment in which the AP-1 site was placed in varying torsional alignments with respect to a reference (sequence-directed) bend (phasing assay; ref. 17). This latter assay yielded 230 for the Fos-Jun-induced bend and 10-12° for the bend induced by the heterodimers. Furthermore, using the phasing assay, Kerppola and Curran (16) observed that the direction of the bend induced by Fos-Jun was nearly opposite to the direction created by the Jun-Jun homodimer, and they suggested that this directionality could contribute to the differential response of the glucocorticoid response element in the presence of Jun (activation) or Fos-Jun (repression). However, using a combination of gel and solution methods, Sitlani and Crothers (5) reached quite a different conclusion regarding the Fos-Jun-AP-1 interaction, namely, that Fos-Jun does not bend its target (i.e., by less than 50). Thus, there actually appear to be two sources of disagreement: one involves a large disparity in the apparent angles derived from permutation and phasing methods; a second involves inconsistent results from phasing and cyclization assays. Since both gel and solution approaches continue to enjoy widespread use, and since the question of Fos-Juninduced bending will necessarily turn on fine points of experimental method, it is worthwhile to consider each method. The details will turn out to be important, not only for Fos-Jun and other members of the bZIP family, but for the study of protein-induced bending of DNA in general.
Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

Lishun Zhang,Zichao Yang,Huiting Sang,Ying Jiang,Mingfeng Zhou,Chuan Huang,Chunhui Huang,Xiaoyun Wu,Tingting Zhang,Xingmei Zhang,Shanhe Wan,Jiajie Zhang

DOI: https://doi.org/10.1080/14756366.2021.1948542

2021-01-01

Journal of Enzyme Inhibition and Medicinal Chemistry

Abstract:Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumour in the central nervous system (CNS). As the ideal targets for GBM treatment, Src family kinases (SFKs) have attracted much attention. Herein, a new series of imidazo[4,5-c]pyridin-2-one derivatives were designed and synthesised as SFK inhibitors. Compounds 1d, 1e, 1q, 1s exhibited potential Src and Fyn kinase inhibition in the submicromolar range, of which were next tested for their antiproliferative potency on four GBM cell lines. Compound 1s showed effective activity against U87, U251, T98G, and U87-EGFRvIII GBM cell lines, comparable to that of lead compound PP2. Molecular dynamics (MDs) simulation revealed the possible binding patterns of the most active compound 1s in ATP binding site of SFKs. ADME prediction suggested that 1s accord with the criteria of CNS drugs. These results led us to identify a novel SFK inhibitor as candidate for GBM treatment.
A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell models

Richard JR Elliott,Peter Nagle,Muhammad Furqan,John C Dawson,Aoife McCarthy,Alison F Munro,Camilla Drake,Gillian M Morrison,Michael Marand,Daniel Ebner,Steve Pollard,Valerie G Brunton,Margaret C Frame,Neil Carragher

DOI: https://doi.org/10.1101/2024.11.27.625719

2024-12-04

Abstract:Despite substantial drug discovery investments, the lack of any significant therapeutic advancement in the treatment of glioblastoma (GBM) over the past two decades calls for more innovation in the identification of effective treatments. The inter- and intra-patient heterogeneity of GBM presents significant obstacles to effective clinical progression of novel treatments by contributing to tumour plasticity and rapid drug resistance that confounds contemporary target directed drug discovery strategies. Phenotypic drug screening is ideally suited to heterogeneous diseases, where targeting specific oncogenic drivers have been broadly ineffective. Our hypothesis is that a modern phenotypic led approach using disease relevant patient derived GBM stem cell systems will be the most productive approach to identifying new therapeutic targets, drug classes and future drug combinations that target the heterogeneity of GBM. In this study we incorporate a panel of patient derived GBM stem cell lines into an automated and unbiased Cell Painting assay to quantify multiple GBM stem cell phenotypes. By screening several compound libraries at multiple concentrations across a panel of patient-derived GBM stem cells we provide the first comprehensive survey of distinct pharmacological classes and known druggable targets, including all clinically approved drug classes and oncology drug candidates upon multiple GBM stem cell phenotypes linked to cell proliferation, survival and differentiation. Our data set representing, 3866 compounds, 2.2million images and 64000 datapoints is the largest phenotypic screen carried out to date on a panel of patient-derived GBM stem cell models that we are aware off. We seek to identify agents and targets classes which engender potent activity across heterogenous GBM genotypes and phenotypes, in this study we further characterize two validated target classes, histone deacetylase inhibitors and cyclin dependent kinases that exert broad and potent effects on the phenotypic and transcriptomic profiles of GBM stem cells. Here we present all validated hit compounds and their target assignments for the GBM community to explore.

Cancer Biology
Stem-18. A High Throughput Neurosphere Based Colony Formation Assay To Validate Drug And Radiation Effectiveness In Patient Derived Xenolines

Manoj Kumar,Joshua Anderson,Hasan Alrefai,Lauren Nassour,Taylor Schanel,Patricia Hicks,Christopher Willey

DOI: https://doi.org/10.1093/neuonc/noae165.0244

2024-11-29

Neuro-Oncology

Abstract:Glioblastoma (GBM) is a primary malignant brain tumor developed from normal astrocytes. GBM patients' median survival is less than 2 years despite safe surgical resection, fractionated conventional radiation, and temozolomide (TMZ) therapy. Few currently used drugs are successful in GBM although there are many FDA approved blood-brain barrier (BBB) penetrant drugs, for other uses that have not been screened in GBM. We utilized a panel of 734 of these BBB penetrant drugs in different GBM patient derived xenolines (PDX) along with acquired radio-resistant derivatives (-RT) including X1441, JX14P, JX14P-RT, JX39P, JX39P-RT and normal human astrocytes (NHA) as control and screened for viability with Cell Titer-Glo. We identified multiple candidate drugs that preferentially killed GBM PDX cells at 10 μM relative to NHA control. As we used stem cell media (serum free) in our drug screening study, it indicates that the potent drugs are also effective in killing cancer stem cells or brain tumor initiating cells. These drugs had targets ranging from PDGFR, DNA/RNA synthesis, as well as other kinase inhibitors. We developed a high throughput (HT), neurosphere based colony formation assay (CFA) in 96-well plate to screen multiple drugs and doses in combination with radiation. For visualizing the colonies, we use a Cytation 5 imager at 4X resolution and count the colonies based on parameters including object size, width, intensity and others. We plan on validating our drug screen and HT-CFA assay with high throughput PamChip kinase activity assays and with in vivo orthotopic tumor PDX models.

oncology,clinical neurology
Spirocamallanus cricotus sp. n. and S. halitrophus sp. n. (Nematoda: Camallanidea) from fishes in the northern Gulf of Mexico.

A. Fusco,R. Overstreet

DOI: https://doi.org/10.2307/3279663

1978-04-01

Journal of Parasitology

Abstract:Spirocamallanus cricotus sp. n. (= S. pereirai, in part) and S. halitrophus sp. n. are described from marine fishes of the northern Gulf of Mexico. Spirocamallanus cricotus has a ledge anterior to the basal ring in the buccal capsule, similar spicules with a ratio of 1:1.4 to 2.1, 3 pre- and 5 postcloacal papillae, and 8 rectal glands in the female; S. halitrophus lacks the ledge and possesses dissimilar spicules with a ratio of 1:1.3 to 1.8, 3 pre- and 6 postcloacal papillae, and 4 rectal glands in the female.
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs

Pengfei Jiang,Rajesh Mukthavavam,Ying Chao,Ila Sri Bharati,Valentina Fogal,Sandra Pastorino,Xiuli Cong,Natsuko Nomura,Matt Gallagher,Taher Abbasi,Shireen Vali,Sandeep C Pingle,Milan Makale,Santosh Kesari

DOI: https://doi.org/10.1186/1479-5876-12-13

IF: 8.44

2014-01-17

Journal of Translational Medicine

Abstract:BackgroundGlioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH clinical collection (NCC) that includes 446 FDA-approved drugs, with the goal of identifying new GBM therapeutics for rapid entry into clinical trials for GBM.MethodsScreens using human GBM cell lines revealed 22 drugs with potent anti-GBM activity, including serotonergic blockers, cholesterol-lowering agents (statins), antineoplastics, anti-infective, anti-inflammatories, and hormonal modulators. We tested the 8 most potent drugs using patient-derived GBM cancer stem cell-like lines. Notably, the statins were active in vitro; they inhibited GBM cell proliferation and induced cellular autophagy. Moreover, the statins enhanced, by 40-70 fold, the pro-apoptotic activity of irinotecan, a topoisomerase 1 inhibitor currently used to treat a variety of cancers including GBM. Our data suggest that the mechanism of action of statins was prevention of multi-drug resistance protein MDR-1 glycosylation. This drug combination was synergistic in inhibiting tumor growth in vivo. Compared to animals treated with high dose irinotecan, the drug combination showed significantly less toxicity.ResultsOur data identifies a novel combination from among FDA-approved drugs. In addition, this combination is safer and well tolerated compared to single agent irinotecan.ConclusionsOur study newly identifies several FDA-approved compounds that may potentially be useful in GBM treatment. Our findings provide the basis for the rational combination of statins and topoisomerase inhibitors in GBM.

medicine, research & experimental
Identification of Rocaglate Acyl Sulfamides as Selective Inhibitors of Glioblastoma Stem Cells

Zihao Wang,Ritesh P Thakare,Shalaka Chitale,Alok K Mishra,Stanley I Goldstein,Alice C Fan,Rui Li,Lihua Julie Zhu,Lauren E Brown,Regina Cencic,Sidong Huang,Michael R Green,Jerry Pelletier,Sunil K Malonia,John A Porco Jr

DOI: https://doi.org/10.1021/acscentsci.4c01073

2024-08-08

Abstract:Glioblastoma (GBM) is the most aggressive and frequently occurring type of malignant brain tumor in adults. The initiation, progression, and recurrence of malignant tumors are known to be driven by a small subpopulation of cells known as tumor-initiating cells or cancer stem cells (CSCs). GBM CSCs play a pivotal role in orchestrating drug resistance and tumor relapse. As a prospective avenue for GBM intervention, the targeted suppression of GBM CSCs holds considerable promise. In this study, we found that rocaglates, compounds which are known to inhibit translation via targeting of the DEAD-box helicase eIF4A, exert a robust, dose-dependent cytotoxic impact on GBM CSCs with minimal killing of nonstem GBM cells. Subsequent optimization identified novel rocaglate derivatives (rocaglate acyl sulfamides or Roc ASFs) that selectively inhibit GBM CSCs with nanomolar EC50 values. Furthermore, comparative evaluation of a lead CSC-optimized Roc ASF across diverse mechanistic and target profiling assays revealed suppressed translation inhibition relative to that of other CSC-selective rocaglates, with enhanced targeting of the DEAD-box helicase DDX3X, a recently identified secondary target of rocaglates. Overall, these findings suggest a promising therapeutic strategy for targeting GBM CSCs.
Dddr-17. A Facile High Throughput Drug Screening Platform Enables The Construction Of A Pharmaco-Proteogenomic Interaction Landscape In Glioblastoma

Ze-Yan Zhang,Yingwen Ding,Ravesanker Ezhilarasan,Melanie Graciani,Aram Modrek,Jerome Karp,Erik Sulman

DOI: https://doi.org/10.1093/neuonc/noae165.0502

2024-11-29

Neuro-Oncology

Abstract:Despite decades of intensive research, the number of treatment options for glioblastoma (GBM), a devastating disease, remains very limited. The vast tumor heterogeneity of GBM and the blood-brain barrier (BBB) represent major hurdles to developing effective therapeutics. Here, we present CARPOOL, a high-throughput therapeutic screening approach designed to facilitate accurate and parallel interrogation of numerous patient-derived GBM spheroid cultures (GSCs), capturing the disease's heterogeneity. We validated CARPOOL in vitro and in vivo and then applied it for drug screening using a library of over 700 BBB-penetrating compounds across 23 omics-profiled GSCs. This screening identified numerous potential anti-GBM compounds, including previously non-oncology drugs. Clustering analysis provided insights into the mechanisms of action of some of the compounds. Coupling these results with omics data of the GSCs enabled the identification of genetic, subtype, and gene expression-based predictors of drug sensitivity. Our study presents a new approach for advancing drug screening and in vivo preclinical therapy evaluation for precision oncology. Furthermore, our construction of a pharmaco-proteogenomic interaction landscape offers a valuable resource for both basic and translational glioblastoma research.

oncology,clinical neurology
DDIS-04. COMPOUNDS IDENTIFIED BY STRUCTURE BASED VIRTUAL SCREENING DECREASE GBM BTIC GROWTH AND GLUCOSE UPTAKE

Catherine Libby,Sixue Zhang,G. C. Sajina,Gloria Benavides,Sarah Scott,Vibha Pathak,Omar Moukha-Chafiq,Yanjie Li,Matthew Redmann,Anh Tran,Arphaxad Otamias,Victor Darley-Usmar,Marek Napierala,Jianhua Zhang,Corinne Augelli-Szafran,Wei Zhang,Anita Hjelmeland

DOI: https://doi.org/10.1093/neuonc/noy148.283

2018-01-01

Neuro-Oncology

Abstract:Patient prognosis for individuals diagnosed with GBM remains incredibly poor with a median survival of only 15 months despite aggressive treatment with surgical tumor resection, chemotherapy, and radiation therapy. Therapeutic development to prolong survival has been hampered by a high degree of inter- and intra-tumoral heterogeneity. Contributing to tumor heterogeneity is a subset of highly tumorigenic cells, termed brain tumor initiating cells (BTICs), that can self-renew and have been shown to be highly invasive and resistant to therapy. BTICs can survive under nutrient poor conditions due to their increased expression of glucose transporter 3 (GLUT3). In a recently accepted study, we utilized structure based virtual screening (SBVS) using a GLUT3 homology model to identify two novel GLUT inhibitors. We are now generating a structure-activity relationship profile based on a highly efficacious compound (IC50= ~300 nM) with the same backbone structure identified in the initial screen and seek to improve the potency, selectivity and drug-like properties of the GLUT inhibitors. We have tested several novel analogs and identified four that have maintained efficacy against BTICs in vitro (IC50= 300–600 nM). Importantly, these analogs have displayed less toxicity to astrocytes than lead compounds in addition to improved stability in mouse liver microsomes. As proof of concept, we have begun to test the GLUT inhibitors alone and in combination with chemotherapy in vivo. Thus far, our work has demonstrated that targeting glucose transport is a promising therapeutic avenue to explore.
Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy

Andrew M. Hersh,Hallie Gaitsch,Safwan Alomari,Daniel Lubelski,Betty M. Tyler

DOI: https://doi.org/10.3390/cancers14153743

2022-08-01

Cancers

Abstract:Glioblastoma (GBM) is an aggressive tumor of the central nervous system categorized by the World Health Organization as a Grade 4 astrocytoma. Despite treatment with surgical resection, adjuvant chemotherapy, and radiation therapy, outcomes remain poor, with a median survival of only 14-16 months. Although tumor regression is often observed initially after treatment, long-term recurrence or progression invariably occurs. Tumor growth, invasion, and recurrence is mediated by a unique population of glioblastoma stem cells (GSCs). Their high mutation rate and dysregulated transcriptional landscape augment their resistance to conventional chemotherapy and radiation therapy, explaining the poor outcomes observed in patients. Consequently, GSCs have emerged as targets of interest in new treatment paradigms. Here, we review the unique properties of GSCs, including their interactions with the hypoxic microenvironment that drives their proliferation. We discuss vital signaling pathways in GSCs that mediate stemness, self-renewal, proliferation, and invasion, including the Notch, epidermal growth factor receptor, phosphatidylinositol 3-kinase/Akt, sonic hedgehog, transforming growth factor beta, Wnt, signal transducer and activator of transcription 3, and inhibitors of differentiation pathways. We also review epigenomic changes in GSCs that influence their transcriptional state, including DNA methylation, histone methylation and acetylation, and miRNA expression. The constituent molecular components of the signaling pathways and epigenomic regulators represent potential sites for targeted therapy, and representative examples of inhibitory molecules and pharmaceuticals are discussed. Continued investigation into the molecular pathways of GSCs and candidate therapeutics is needed to discover new effective treatments for GBM and improve survival.

oncology
Relationship between antenatal group B streptococcal vaginal colonization and premature labour.

U. Allen,C. Nimrod,N. Macdonald,B. Toye,D. Stephens,V. Marchessault

DOI: https://doi.org/10.1093/PCH/4.7.465

1999-10-01

Paediatrics & Child Health

Abstract:OBJECTIVE To determine whether a population of pregnant women with group B streptococcal (GBS) vaginal colonization had an increased risk of specific epidemiological and intrapartum risk factors for early onset GBS disease. SETTING Tertiary university centre in Ottawa, Ontario. DESIGN Hospital-based retrospective cohort study. METHODS Pregnant women who gave birth during a four-month period in 1994 were included in the study. Potential GBS risk factors were obtained from a review of medical records. The prevalence of each risk factor in colonized and noncolonized women was examined using chi(2) or Fisher's exact test. Multiple logistic regression was performed. RESULTS A total of 986 women, including 94 (9.5%) women colonized with GBS, were studied. The proportion of women younger than 20 years of age in the colonized group was 2.1% (two of 94) versus 4.6% (41 of 891) in the noncolonized group (P=0.28). Similar rates of multiple births were observed among the colonized and noncolonized groups (2.1% [two of 94] versus 2.5% [22 of 891], respectively) (P=0.94). Likewise, there were no significant differences in either group in the prevalence of a previous pregnancy affected by GBS or diabetes mellitus (P=0.82 and P=0.79, respectively). Multivariable analyses indicated that women who were colonized with GBS were more than twice as likely to deliver prematurely (below 37 weeks' gestational age) (odds ratio [OR] 2.43, 95% CI 1.39 to 4.23). Similarly, colonized women were more likely to be febrile during labour (at least 38 degrees C) (OR 5.05, 95% CI 1.70 to 15.02). CONCLUSION GBS vaginal colonization was associated with premature labour and intrapartum pyrexia in the population studied. According to Canadian and American guidelines, women with GBS vaginal colonization qualify for intrapartum chemoprophylaxis. The study results suggest that the identification of women at risk of premature labour may be one advantage of early prenatal screening for GBS.
Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy

Kelli M. Wilson,Lesley A. Mathews-Griner,Tara Williamson,Rajarshi Guha,Lu Chen,Paul Shinn,Crystal McKnight,Sam Michael,Carleen Klumpp-Thomas,Zev A. Binder,Marc Ferrer,Gary L. Gallia,Craig J. Thomas,Gregory J. Riggins

DOI: https://doi.org/10.1177/2472630318803749

IF: 2.813

2019-02-01

SLAS TECHNOLOGY

Abstract:Glioblastoma (GBM) is a lethal brain cancer with a median survival time of approximately 15 months following treatment. Common in vitro GBM models for drug screening are adherent and do not recapitulate the features of human GBM in vivo. Here we report the genomic characterization of nine patient-derived, spheroid GBM cell lines that recapitulate human GBM characteristics in orthotopic xenograft models. Genomic sequencing revealed that the spheroid lines contain alterations in GBM driver genes such as PTEN, CDKN2A, and NF1. Two spheroid cell lines, JHH-136 and JHH-520, were utilized in a high-throughput drug screen for cell viability using a 1912-member compound library. Drug mechanisms that were cytotoxic in both cell lines were Hsp90 and proteasome inhibitors. JHH-136 was uniquely sensitive to topoisomerase 1 inhibitors, while JHH-520 was uniquely sensitive to Mek inhibitors. Drug combination screening revealed that PI3 kinase inhibitors combined with Mek or proteasome inhibitors were synergistic. However, animal studies to test these drug combinations in vivo revealed that Mek inhibition alone was superior to the combination treatments. These data show that these GBM spheroid lines are amenable to high-throughput drug screening and that this dataset may deliver promising therapeutic leads for future GBM preclinical studies.

biochemical research methods,chemistry, analytical
Abstract 3503: New generation drug development from in-silico identification to preclinical evaluation in glioblastoma

Mahesh Arunachalam,Shreyas Gaikwad,Sharavan Ramachandran,Sanjay K. Srivastava

DOI: https://doi.org/10.1158/1538-7445.am2024-3503

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Glioblastoma(GBM) is the most common malignancy of the central nervous system in adults. Despite medical advancements, stagnant survival rate improvements (<13%) and failure of conventional treatments such as temozolomide, have warranted the need for novel drug discovery methodologies. Considering the enormous potential of drug repurposing, we developed a method to identify a safe, active, and effective treatment for GBM. This method comprises two key stages, drug-target prediction and preclinical functional evaluation. Stage 1 fabricated a novel five phase in-silico pipeline for drug-target prediction against Ephrin-Type-A Receptor 2, chosen through preliminary literature and genomic analysis. Around 1562 FDA approved drugs were screened against the developed criterion and analyzed for bond type, location, repulsion, Gibbs free energy, stability, interactions over time, blood brain barrier permeability, and possible false positives (PAINS). Our results provided five plausible hits: Empagliflozin, Mycophenolate mofetil, Canagliflozin, Rivaroxaban, and Carvedilol. We subsequently evaluated the anti-proliferative effects of these hits using Sulforhodamine-B cytotoxicity assay on glioblastoma cell lines U251 and SF295. Our results demonstrated that Canaglifozin and Empagliflozin reduced the proliferation of GBM cell lines with IC50 value ranging from 30-40 μM. On the other hand, Mycophenolate mofetil (IC50: 5μM) and Carvedilol (IC50:16μM) also exhibited significant cytotoxic effects. Effects of Mycophenolate mofetil and Carvedilol were further evaluated in pancreatic cell line SUIT-2 where results exhibited cytotoxic responses similar to those observed in GBM. Furthermore, Annexin V/FITC analysis showed apoptosis in SUIT-2 cells by Carvedilol. Taken together, our results show the anti-cancer repurposing candidates extracted from our in-silico pipeline show significant cytotoxic effects of compounds identified through in-silico screening. Further studies are currently underway in our laboratory to delineate the anti-cancer mechanism, toxicity and off-target effects of these compounds. Citation Format: Mahesh Arunachalam, Shreyas Gaikwad, Sharavan Ramachandran, Sanjay K. Srivastava. New generation drug development from in-silico identification to preclinical evaluation in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3503.

oncology
Abstract LB432: Identification of novel drug targets using the ADAPT biotargeting system on FFPE tissue from patients with glioblastoma multiforme

Xixi Wei,Myunggi An,Radhika Santhanam,Barbara Richardson,Lucas Vu,Justin Saul,Anna Walton,Michael Gee,Daniel Martin,Amanda Hubbard,Alexis Rodin,Matthew Rosenow,Tassilo Hornung

DOI: https://doi.org/10.1158/1538-7445.am2024-lb432

IF: 11.2

2024-04-07

Cancer Research

Abstract:Glioblastoma Multiforme (GBM) is one of the most aggressive and lethal brain tumor types with a five-year survival rate of 6.9%. In 2023, more than 14,490 Americans were expected to receive a diagnosis. Although great progress has been achieved in protein target identification and treatment over the last few years, current treatment options are limited, and tumor recurrence occurs at a high rate due to treatment resistance. Aptamers, short single-stranded oligonucleotide ligands with high-affinity binding to molecular targets, are well suited tools for exploring novel targets in highly heterogeneous tumors with complex etiologies like GBM, where clinically relevant biomarkers are limited. In this study, aptamer-based cancer-specific drug target identification was performed by Adaptive Dynamic Artificial Polyligand Targeting (ADAPT) Biotargeting System. In short, a GBM-specific library was enriched through a Systematic Evolution of Ligands by EXponential enrichment (SELEX) process using micro dissected Formalin-Fixed Paraffin-Embedded (FFPE) tissues from GBM patients, along with whole body normal tissue for counterselection. Microdissection of tissue allows the partitioning of different types of cells to focus on specific cells of interest. The enriched libraries have been evaluated on clinical GBM and normal brain control samples through aptamer mediated tissue staining, resulting in preferential binding of enriched libraries compared to controls in the vast majority of GBM patients with little binding to normal brain samples. The final library was subsequently applied in an in-house developed library-based affinity pull-down assay using lysates from FFPE tissue of the same group of GBM patients and normal brain samples, followed by unbiased Mass Spectrometry for protein target identification. Combining the results from this proteomics analysis and data from the internal Whole Transcriptome Sequencing (WTS) database, we were able to identify several targets that are highly expressed in GBM and other cancer lineages. Antibody staining provided further validation of the expression levels and the cellular localization. The targets identified in this study include not only potential novel therapeutic targets, but also well-studied biomarkers and targets with available drugs already in clinical trials, demonstrating the platform has great potential for identifying high affinity binding and selectivity compared to traditional proteomics and other methods in drug target discovery. Citation Format: Xixi Wei, Myunggi An, Radhika Santhanam, Barbara Richardson, Lucas Vu, Justin Saul, Anna Walton, Michael Gee, Daniel Martin, Amanda Hubbard, Alexis Rodin, Matthew Rosenow, Tassilo Hornung. Identification of novel drug targets using the ADAPT biotargeting system on FFPE tissue from patients with glioblastoma multiforme [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB432.

oncology
High-throughput glycolytic inhibitor discovery targeting glioblastoma by graphite dots–assisted LDI mass spectrometry

Rui Shi,Peichen Pan,Rui Lv,Chongqing Ma,Enhui Wu,Ruochen Guo,Zhihao Zhao,Hexing Song,Joe Zhou,Yang Liu,Guoqiang Xu,Tingjun Hou,Zhenhui Kang,Jian Liu

DOI: https://doi.org/10.1126/sciadv.abl4923

IF: 13.6

2022-02-18

Science Advances

Abstract:Malignant tumors will become vulnerable if their uncontrolled biosynthesis and energy consumption engaged in metabolic reprogramming can be cut off. Here, we report finding a glycolytic inhibitor targeting glioblastoma with graphite dots–assisted laser desorption/ionization mass spectrometry as an integrated drug screening and pharmacokinetic platform (GLMSD). We have performed high-throughput virtual screening to narrow an initial library of 240,000 compounds down to the docking of 40 compounds and identified five previously unknown chemical scaffolds as promising hexokinase-2 inhibitors. The best inhibitor (Compd 27) can regulate the reprogrammed metabolic pathway in U87 glioma cells (median inhibitory concentration ~ 11.3 μM) for tumor suppression. Highly effective therapy against glioblastoma has been demonstrated in both subcutaneous and orthotopic brain tumors by synergizing Compd 27 and temozolomide. Our glycolytic inhibitor discovery can inspire personalized medicine targeting reprogrammed metabolisms of malignant tumors. GLMSD enables large, high-quality data for next-generation artificial intelligence–aided drug development.

multidisciplinary sciences
RSVP Standards Today and the Path Towards a Generic Messenger

Xiaoming Fu,J. Manner

DOI: https://doi.org/10.1007/11499169_40

2005-06-21

Abstract:
Abstract 5443: Identifying key regulators of glioblastoma cancer stem cells

Tao Wang,Xuanhua Xie,Luis F. Parada

DOI: https://doi.org/10.1158/1538-7445.am2024-5443

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Glioblastoma multiforme (GBM) has a dire prognosis that has had little progress over the past three decades. The existence of a unique population of stem-like gene signature baring quiescent cells (GSCs) within GBM are important for GBM tumorigenesis, therapy-resistance and recurrence. Our lab has developed one of the most faithful genetically engineered mouse models, encompassing a Nestin promoter-enhancer driven CreERT2-H2BeGFP-hDTR cassette (hereafter as CGD), that allows us to accurately capture and isolate GSCs in mouse GBM. The next logical step is to leverage these tools to uncover therapeutic vulnerabilities of GSCs and make a meaningful impact on GBM patient outcomes. To our knowledge, very few studies have explored the functional regulators of GSCs using a CRISPR/Cas9 screening approach. Our GSC signature provides a strong foundation for performing targeted in vitro or in vivo screens. In this study, to identify functionally important genes that may regulate GSC self-renewal and tumorigenic properties, an in vitro CRISPR knockout screens using a gene library derived from the GSC signature. The viral library was applied to low passage primary cultures of FACS sorted CGD_GFP+ and CGD_GFP- GBM cells developed from CGD; Nf1f/+;Trp53f/f;Ptenf/+ mice, respectively. The result of our in vitro CRISPR knock-out screen demonstrated guide depletion of Atp1b2-sgRNA in CGD_GFP+ but not in CGD_GFP- cells. The main objective of this study is to utilize in vitro and in vivo functional assays to test the difference between Atp1b2 WT and Atp1b2 KO GSCs and Atp1b2 WT vs KO GSC-derived tumors. Having a targeted candidate gene list is also particularly helpful for designing an in vivo CRISPR knockout screen, which is more physiological relevant. Therefore, I propose to use the candidate gene list derived from the in vitro screen as a starting point. The in vivo screen can provide valuable insights for the selection of the most optimal candidates for anti-GSC therapies. Citation Format: Tao Wang, Xuanhua Xie, Luis F. Parada. Identifying key regulators of glioblastoma cancer stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5443.

oncology

Inbreeding and sex: Canalization, plasticity and sexual selection

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

Clinical evaluation of Amerlite's one-step immunoassay for determining free thyroxin.

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Do basic region-leucine zipper proteins bend their DNA targets ... does it matter?

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell models

Stem-18. A High Throughput Neurosphere Based Colony Formation Assay To Validate Drug And Radiation Effectiveness In Patient Derived Xenolines

Spirocamallanus cricotus sp. n. and S. halitrophus sp. n. (Nematoda: Camallanidea) from fishes in the northern Gulf of Mexico.

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs

Identification of Rocaglate Acyl Sulfamides as Selective Inhibitors of Glioblastoma Stem Cells

Dddr-17. A Facile High Throughput Drug Screening Platform Enables The Construction Of A Pharmaco-Proteogenomic Interaction Landscape In Glioblastoma

DDIS-04. COMPOUNDS IDENTIFIED BY STRUCTURE BASED VIRTUAL SCREENING DECREASE GBM BTIC GROWTH AND GLUCOSE UPTAKE

Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy

Relationship between antenatal group B streptococcal vaginal colonization and premature labour.

Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy

Abstract 3503: New generation drug development from in-silico identification to preclinical evaluation in glioblastoma

Abstract LB432: Identification of novel drug targets using the ADAPT biotargeting system on FFPE tissue from patients with glioblastoma multiforme

High-throughput glycolytic inhibitor discovery targeting glioblastoma by graphite dots–assisted LDI mass spectrometry

RSVP Standards Today and the Path Towards a Generic Messenger

Abstract 5443: Identifying key regulators of glioblastoma cancer stem cells